-
Study of RET Inhibitor TAS0953/HM06 in Patients With Advanced Solid Tumors With RET Gene Abnormalities
Not Recruiting
More
Phase 1 and 2 trial to study the safety, pharmacokinetics, and efficacy of TAS0953/HM06 in
patients with advanced solid tumors with RET gene abnormalities. Phase 1 aims to determine
the Maximum Tolerated Dose (MTD) and identify the Recommended Phase 2 Dose (RP2D) to be used
in phase 2.
Stanford is currently not accepting patients for this trial.
For more information, please contact Heather Ann Wakelee, MD, .
Stanford Investigators
View full details
-
A Study of Atezolizumab and Tiragolumab Compared With Durvalumab in Participants With Locally Advanced, Unresectable Stage III Non-Small Cell Lung Cancer (NSCLC)
Recruiting
More
The purpose of this study is to evaluate the efficacy and safety of atezolizumab in
combination with tiragolumab compared with durvalumab in participants with locally advanced,
unresectable Stage III non-small cell lung cancer (NSCLC) who have received at least two
cycles of concurrent platinum-based chemoradiotherapy (CRT) and have not had radiographic
disease progression.
Stanford Investigators
View full details
-
Phase II Randomized Trial of Carboplatin+Pemetrexed+Bevacizumab+/- Atezolizumab in Stage IV NSCLC
Recruiting
More
While cigarette smoking remains the primary cause of most lung cancer cases, lung carcinoma
in never smokers account for nearly 20 percent of cases. Never smokers with lung cancer
typically present with different molecular profiles from that of smokers, which results in
prognostic and therapeutic implications. Molecular changes in NSCLC that have therapeutic
significance include mutations in the epidermal growth factor receptor (EGFR) and
rearrangements in the anaplastic lymphoma kinase (ALK) gene. These driver mutations typically
are present in lung tumors found in never or light smokers.
The addition of bevacizumab to carboplatin and paclitaxel in first-line treatment of
non-squamous NSCLC showed improved survival compared to carboplatin and paclitaxel alone,
12.3 vs. 10.3 months respectively. Results from the POINTBREAK trial demonstrated that
carboplatin + pemetrexed + bevacizumab is an alternative option to carboplatin + paclitaxel +
bevacizumab, with comparable survival but less toxicity. In recent years, immunotherapy has
emerged as a form of treatment that can lead to robust responses in a subset of patients. The
PD-1 inhibitor nivolumab and the PD-L1 inhibitor atezolizumab have shown prolonged survival
in comparison to docetaxel in patients who previously progressed with chemotherapy,
irrespective of PD-L1 expression. Thus, this study combines immunotherapeutic agent
atezolozumab with an ant-angiogenic agent, bevacizumab, and double platinum therapy
(carboplatin and pemetrexed).
Stanford Investigators
View full details
-
Phase I/II Eval Safety & Prelim Activity Nivolumab Comb W/Vorolanib Pts W/Refractory Thoracic Tumors
Not Recruiting
More
This is a two-agent, open-label, non-randomized, Phase 1/2 dose escalation and dose expansion
study of combinatorial oral vorolanib plus infusional nivolumab in patients with Non-Small
Cell Lung Cancer naïve to checkpoint inhibitor therapy, Non-Small Cell Lung Cancer who have
progressed on checkpoint inhibitor therapy, Small Cell Lung Cancer ( who have progressed on
platinum-based chemotherapy, and thymic carcinoma.
Stanford is currently not accepting patients for this trial.
For more information, please contact Cancer Clinical Trials Office (CCTO), 650-498-7061.
Stanford Investigators
View full details
-
Expanded Access to Ensartinib for Participants With ALK+ NSCLC
Not Recruiting
More
This is an open-label, multicenter, intermediate-sized expanded access treatment protocol to
the existing IND 111,695 for ensartinib (X-396). The treatment plan is designed to provide
ensartinib to participants with anaplastic lymphoma kinase (ALK)-rearranged non-small cell
lung cancer (NSCLC).
Stanford is currently not accepting patients for this trial.
For more information, please contact Richard Quick, 650-723-2983.
Stanford Investigators
View full details
-
Grapiprant (ARY-007) and Pembrolizumab in Patients With Advanced or Metastatic Post-PD-1/L1 NSCLC Adenocarcinoma
Not Recruiting
More
This study will be conducted in adult participants diagnosed with NSCLC who have been
previously treated for a minimum of 12 weeks with any PD-1 or PD-L1 checkpoint inhibitor.
This is a phase 1b/2, multi-center, open label study designed to assess safety and
tolerability of grapiprant in combination with pembrolizumab, to determine the recommended
phase 2 dose (RP2D) with pembrolizumab, and to evaluate disease response with grapiprant
based on investigator assessments. Pharmacokinetics, pharmacodynamics and response biomarkers
will also be assessed.
Stanford is currently not accepting patients for this trial.
For more information, please contact Melanie San Pedro, 650-724-1388.
Stanford Investigators
View full details
-
A Study of Weekly Tisotumab Vedotin for Patients With Platinum-Resistant Ovarian Cancer With Safety Run-in (innovaTV 208)
Not Recruiting
More
This trial will study tisotumab vedotin to find out what its side effects are and to see if
it works for platinum-resistant ovarian cancer (PROC). It will test different doses of
tisotumab vedotin that are given at different times. It will also compare the side effects
and ability to treat tumors of these different doses and schedules. In this study, there will
be a safety run-in group of approximately 12 patients that will look at a dose-dense
treatment schedule. In a dose-dense schedule, smaller doses are given more frequently. In
addition to the safety run-in patients, there will be three groups in the study. One group
will get tisotumab vedotin once every 3 weeks (21-day cycles). The two other groups will get
tisotumab vedotin once a week for 3 weeks followed by 1 week off (28-day cycles).
Stanford is currently not accepting patients for this trial.
For more information, please contact Ann Moffat, 669-233-2816.
Stanford Investigators
View full details
-
Efficacy and Safety of Pembrolizumab (MK-3475) With Platinum Doublet Chemotherapy as Neoadjuvant/Adjuvant Therapy for Participants With Resectable Stage II, IIIA, and Resectable IIIB (T3-4N2) Non-small Cell Lung Cancer (MK-3475-671/KEYNOTE-671)
Not Recruiting
More
This trial will evaluate the safety and efficacy of pembrolizumab (MK-3475) in combination
with platinum doublet neoadjuvant chemotherapy (NAC) before surgery [neoadjuvant phase],
followed by pembrolizumab alone after surgery [adjuvant phase] in participants with
resectable stage II, IIIA, and resectable IIIB (T3-4N2) non-small cell lung cancer (NSCLC).
The primary hypotheses of this study are that neoadjuvant pembrolizumab (vs. placebo) in
combination with NAC, followed by surgery and adjuvant pembrolizumab (vs. placebo) will
improve: 1) event free survival (EFS) by biopsy assessed by local pathologist or by
investigator-assessed imaging using Response Evaluation Criteria in Solid Tumors Version 1.1
(RECIST 1.1); and 2) overall survival (OS).
Stanford is currently not accepting patients for this trial.
For more information, please contact Study Coordinator, 650-736-7221.
Stanford Investigators
View full details
-
Regorafenib and Methotrexate in Treating Participants With Recurrent or Metastatic KRAS Mutated Non-Small Cell Lung Cancer
Not Recruiting
More
This phase II trial studies how well regorafenib works together with methotrexate in treating
participants with metastatic non-squamous non-small cell lung cancer with tumors that harbor
a KRAS mutation. Regorafenib is a targeted therapy that works on different cancer pathways to
stop the growth of tumor cells and stop them from spreading. Methotrexate may stop the growth
of tumor cells by blocking some of the enzymes needed for cell growth. Giving regorafenib and
methotrexate together may work in treating participants with KRAS mutated non-small cell lung
cancer.
Stanford is currently not accepting patients for this trial.
For more information, please contact Grace Hwang, 650-723-0437.
Lead Sponsor
Stanford Investigators
View full details
-
Radiation Therapy in Preventing Central Nervous System (CNS) Metastases in Patients With Non-Small Cell Lung Cancer
Not Recruiting
More
RATIONALE: Radiation therapy uses high-energy x-rays to damage tumor cells. It is not yet
known if giving radiation therapy to the head is effective in preventing CNS metastases in
patients who have stage III non-small cell lung cancer.
PURPOSE: This randomized phase III trial is studying how well radiation therapy to the head
works in preventing CNS metastases in patients who have been previously treated for stage III
non-small cell lung cancer.
Stanford is currently not accepting patients for this trial.
For more information, please contact Derek Huang, 6507250203.
Stanford Investigators
View full details
-
Radiation Therapy in Treating Patients With Extensive Stage Small Cell Lung Cancer
Not Recruiting
More
RATIONALE: Radiation therapy uses high energy x-rays to kill tumor cells. This may be an
effective treatment for extensive stage small cell lung cancer.
PURPOSE: This randomized phase II trial is comparing how well radiation therapy to the brain
works when given with or without radiation therapy to other areas of the body in treating
patients with extensive stage small cell lung cancer.
Stanford is currently not accepting patients for this trial.
For more information, please contact Laura Gable, 6507360798.
Stanford Investigators
View full details
-
ExAblate Conformal Bone System Treatment of Metastatic Bone Tumors for the Palliation of Pain
Not Recruiting
More
A study to evaluate the safety and initial effectiveness of the ExAblate 2100 Conformal Bone
System in the treatment of pain resulting from metastatic bone tumors.
Stanford is currently not accepting patients for this trial.
For more information, please contact Fizaa Ahmed, 650-725-6409.
Stanford Investigators
View full details
-
MAGE A10ᶜ⁷⁹⁶T for Advanced NSCLC
Recruiting
More
This first time in human study is intended for men and women at least 18 years of age who
have advanced lung cancer which has grown or returned after being treated. In particular, it
is a study for subjects who have a blood test positive for HLA-A*02:01 and/or HLA-A*02:06 and
a tumor test positive for MAGE A10 protein expression (protein or gene). This trial is a dose
escalation trial that will evaluate 3 doses of transduced cells administered after a
lymphodepleting chemotherapy regimen using a 3+3 dose escalation design .The study will take
the subject's T cells, which are a natural type of immune cell in the blood, and send them to
a laboratory to be modified. The changed T cells used in this study will be the subject's own
T cells that have been genetically changed with the aim of attacking and destroying cancer
cells.
When the MAGE A10ᶜ⁷⁹⁶T cells are available, subjects will receive lymphodepleting
chemotherapy with cyclophosphamide and fludarabine, followed by the T cell infusion. The
purpose of this study is to test the safety of genetically changed T cells and find out what
effects, if any, they have in subjects with lung cancer. The study will evaluate three
different cell dose levels in order to find out the target cell dose. Once the target cell
dose is determined, additional subjects will be enrolled to further test the safety and
effects at this cell dose.
Subjects will be seen frequently by the Study Physician right after receiving their T cells
back and up to first 6 months. After that, subjects will be seen every three months. Subjects
will be seen every 6 months by their Study Physician for the first 5 years after the T cell
infusion. If the T cells are found in the blood at five years, then the subjects will
continue to be seen once a year until the T cells are no longer found in the blood for a
maximum of 15 years. If the T cells are no longer found in the blood at 5 years, then the
subject will be contacted by the Study Physician for the next 10 years. Subjects who have a
confirmed response or clinical benefit ≥4 weeks after the first T-cell infusion and whose
tumor continues to express the appropriate antigen target may be eligible for a second
infusion. All subjects, completing or withdrawing from the Interventional Phase of the study,
will enter a 15-year long-term follow-up phase for observation of delayed adverse events. All
subjects will continue to be followed for overall survival during the long-term follow-up
phase.
Stanford Investigators
View full details
-
A Phase 1 Dose Escalation Study of OMP-21M18 in Subjects With Solid Tumors
Not Recruiting
More
A phase 1 open-label dose escalation study of OMP-21M18 in subjects with previously treated
solid tumour for which there is no remaining standard curative therapy and no therapy with a
demonstrated survival benefit.
Stanford is currently not accepting patients for this trial.
For more information, please contact Dana Supan, 6507361694.
Stanford Investigators
View full details
-
A 3rd/4th Line Placebo-controlled Trial of Sorafenib in Patients With Predominantly Non Squamous Non-Small Cell Lung Cancer (NSCLC).
Not Recruiting
More
The purpose of the study is to see if sorafenib plus best supportive care (i.e. in addition
to the non-cancer treatments patients would normally receive) is an effective treatment for
lung cancer compared to best supportive care alone. The safety and tolerability of the two
treatment groups will also be compared. The goal of the study is to test the ability of
sorafenib to improve survival compared to best supportive care alone.
Stanford is currently not accepting patients for this trial.
For more information, please contact Melanie San Pedro-Salcedo, 6507241388.
Stanford Investigators
View full details
-
A Study of HGS1029 (AEG40826-2HCl) in Subjects With Advanced Solid Tumors
Not Recruiting
More
The purpose of this study is to evaluate the safety and tolerability of HGS1029 in subjects
with advanced solid tumors and to determine a phase 2 dose.
Stanford is currently not accepting patients for this trial.
For more information, please contact Dana Supan, 6507361694.
Stanford Investigators
View full details
-
QUILT-3.026: AMG 655 in Combination With AMG 479 in Advanced, Refractory Solid Tumors
Not Recruiting
More
This is a multi-center, 2-part phase 1b/2 study of AMG 655 in combination with AMG 479 to be
conducted in the United States and Spain.
Part 1 is a dose escalation segment to identify a dose of AMG 655 in combination with AMG 479
that is safe and tolerable.
Part 2 will evaluate the safety and estimate the efficacy of AMG 655 at the dose selected in
Part 1 in combination with AMG 479 for the treatment of patients with advanced NSCLC
(non-squamous histology; squamous histology), CRC, pancreatic cancer, ovarian cancer, and
sarcoma.
Stanford is currently not accepting patients for this trial.
For more information, please contact Dana Supan, 6507361694.
Stanford Investigators
View full details
-
Efficacy and Safety Study of Tisotumab Vedotin for Patients With Solid Tumors
Not Recruiting
More
This trial will study tisotumab vedotin to find out whether it is an effective treatment for
certain solid tumors and what side effects (unwanted effects) may occur. There are seven
parts to this study.
- In Part A, the treatment will be given to participants every 3 weeks (3-week cycles).
- In Part B, participants will receive tisotumab vedotin on Days 1, 8, and 15 every 4-week
cycle.
- In Part C, participants will receive tisotumab vedotin on Days 1 and 15 of every 4-week
cycle.
- In Part D, participants will be given treatment on Day 1 of every 3-week cycle.
Participants in Part D will get tisotumab vedotin with either:
- Pembrolizumab or,
- Pembrolizumab and carboplatin, or
- Pembrolizumab and cisplatin
- In Part E, participants will receive tisotumab vedotin on Days 1 and 15 of every 4-week
cycle.
- In Part F, participants will receive tisotumab vedotin on Days 1, 15, and 29 of every
6-week cycle. Participants in Part F will get tisotumab vedotin with pembrolizumab.
- In Part G, participants will receive tisotumab vedotin on Days 1, 15, and 29 of every
6-week cycle. Participants in Part G will get tisotumab vedotin with pembrolizumab and
carboplatin.
Stanford is currently not accepting patients for this trial.
For more information, please contact Cancer Clinical Trials Office (CCTO), 650-498-7061.
Stanford Investigators
View full details
-
Safety, Pharmacokinetic and Preliminary Efficacy Study of AC0010MA in Advanced Non Small Cell Lung Cancer
Not Recruiting
More
AC0010MA is a new, irreversible, Epidermal Growth Factor Receptor (EGFR) mutation selective
Tyrosine Kinase Inhibitor. Aim at local advanced or metastatic non-small cell lung cancer
patients with EGFR mutation or T790M drug-resistant mutation. The molecular mechanism: by
irreversible combining the EGFR-RTKs ATP binding site of cell, selectively suppress the
activities of EGFR tyrosine kinase phosphorylation, block the signal transduction pathway of
EGFR and inhibit the function of ras/raf/MAPK downstream, thus block the tumor cell growth by
EGFR induction, and promotes apoptosis. AC0010MA Maleate Capsules has three characters: 1.
Irreversible binding to EGFR; 2. Effectively suppresses the tumor cell with EGFR mutant while
has no suppression to EGFR wild-type cell; 3. Efficient suppress the tumor cell with EGFR
T790M drug-resistant mutation.
Stanford is currently not accepting patients for this trial.
For more information, please contact Cancer Clinical Trials Office (CCTO), 650-498-7061.
Stanford Investigators
View full details
-
A Study of Atezolizumab in Participants With Programmed Death-Ligand 1 (PD-L1) Positive Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) [FIR]
Not Recruiting
More
This multicenter, single-arm study will evaluate the efficacy and safety of atezolizumab
(MPDL3280A) in participants with PD-L1-positive locally advanced or metastatic NSCLC.
Participants will receive an intravenous (IV) dose of 1200 milligrams (mg) atezolizumab
(MPDL3280A) on Day 1 of 21-day cycles until disease progression.
Eligible participants will be categorized in to three groups as follows:
1. Participants with no prior chemotherapy for advanced disease;
2. Participants who progress during or following a prior-platinum based chemotherapy
regimen for advanced disease (2L+participants);
3. Participants who are 2L+ and previously treated for brain metastases.
Stanford is currently not accepting patients for this trial.
For more information, please contact Lisa Zhou, 650-736-4112.
Stanford Investigators
View full details
-
PDR001 in Combination With Platinum-doublet Chemotherapy and Other Immunology Agents in PD-L1 Unselected, Metastatic NSCLC Patients
Not Recruiting
More
The primary purpose of this study is to establish the maximum tolerated dose (MTD) and/or
recommended dose for expansion (RDE) of PDR001 when administered in combination with
platinum-doublet chemotherapy and other immunooncology agent(s) in treatment naive patients
with PD-L1 unselected, advanced NSCLC, and to estimate the preliminary anti-tumor activity in
this patient population.
Stanford is currently not accepting patients for this trial.
For more information, please contact Cancer Clinical Trials Office (CCTO), 650-498-7061.
Stanford Investigators
View full details
-
Nexavar® Versus Placebo in Locally Advanced/Metastatic RAI-Refractory Differentiated Thyroid Cancer
Not Recruiting
More
Trial of sorafenib versus placebo in the treatment of locally advanced or metastatic
differentiated thyroid cancer refractory to radioiodine
Stanford is currently not accepting patients for this trial.
For more information, please contact Ruth Lira, 6507231367.
Stanford Investigators
View full details
-
Octreotide Acetate and Recombinant Interferon Alfa-2b or Bevacizumab in Treating Patients With Metastatic or Locally Advanced, High-Risk Neuroendocrine Tumor
Not Recruiting
More
This randomized phase III trial studies octreotide acetate and recombinant interferon alfa-2b
to see how well it works compared to octreotide acetate and bevacizumab in treating patients
with high-risk neuroendocrine tumors that have spread to other places in the body
(metastatic) or spread from where it started to nearby tissue or lymph nodes (locally
advanced). Octreotide acetate and recombinant interferon alfa-2b may interfere with the
growth of tumor cells and slow the growth of cancer. Monoclonal antibodies, such as
bevacizumab, may interfere with the ability of tumor cells to grow and spread. It is not yet
known whether giving octreotide acetate together with recombinant interferon alfa-2b is more
effective than giving octreotide acetate together with bevacizumab in treating patients with
neuroendocrine tumor.
Stanford is currently not accepting patients for this trial.
For more information, please contact Deryn Warner, 6507232876 x 25067.
Stanford Investigators
View full details
-
Osimertinib and Necitumumab in Treating Patients With EGFR-Mutant Stage IV or Recurrent Non-small Cell Lung Cancer Who Have Progressed on a Previous EGFR Tyrosine Kinase Inhibitor
Not Recruiting
More
This phase I trial studies the side effects and best dose of necitumumab when given together
with osimertinib in treating patients with EGFR-mutant non-small cell lung cancer that is
stage IV or has come back after a period of improvement (recurrent) and who have progressed
on a previous EGFR tyrosine kinase inhibitor. Immunotherapy with monoclonal antibodies, such
as necitumumab, may induce changes in body's immune system and may interfere with the ability
of tumor cells to grow and spread. Osimertinib may stop the growth of tumor cells by blocking
some of the enzymes needed for cell growth. Giving necitumumab with osimertinib may be a
better treatment for EGFR-mutant non-small cell lung cancer.
Stanford is currently not accepting patients for this trial.
For more information, please contact Sukhmani K. Padda, 650-498-7061.
Stanford Investigators
View full details
-
Erlotinib in Patients With Resected, Early Stage NSCLC With Confirmed Mutations in the EGFR
Not Recruiting
More
In this research study erlotinib will be given to eligible participants whose lung cancer has
been removed by surgery. Eligible patients have adenocarcinoma, a type of non-small lung
cancer, and must have 1 or more of the following characteristics: be female, be of Asian or
Pacific Rim descent and/or be a never smoker. The potential participant's tumor will be
examined for Epidermal growth factor (EGFR) mutations. EGFR is a protein that is
overexpressed in most non-small cell lung cancers. Some EGFR has been found to have specific
mutations and the participant must have one of these mutations in his tumor.
Erlotinib blocks this protein and may control tumor growth and increase survival. Previous
research has shown that erlotinib is most effective for people who have these specific
mutations in the EGFR.
Stanford is currently not accepting patients for this trial.
For more information, please contact Lei Shura, 650-723-2312.
Stanford Investigators
View full details
-
A Study of Atezolizumab (an Engineered Anti-Programmed Death-Ligand 1 [PDL1] Antibody) to Evaluate Safety, Tolerability and Pharmacokinetics in Participants With Locally Advanced or Metastatic Solid Tumors
Not Recruiting
More
This Phase I, multicenter, first-in-human, open-label, dose-escalation study will evaluate
the safety, tolerability, and pharmacokinetics of atezolizumab (MPDL3280A) administered as
single agent to participants with locally advanced or metastatic solid malignancies or
hematologic malignancies. The study will be conducted in two cohorts: Dose-escalation cohort
and Expansion cohort.
Stanford is currently not accepting patients for this trial.
For more information, please contact Maria Pitsiouni, 650-721-6977.
Stanford Investigators
View full details
-
Bevacizumab or Pemetrexed Disodium Alone or In Combination After Induction Therapy in Treating Patients With Advanced Non-Squamous Non-Small Cell Lung Cancer
Not Recruiting
More
RATIONALE: Drugs used in chemotherapy, such as paclitaxel and carboplatin, work in different
ways to stop the growth of tumor cells, either by killing the cells or by stopping them from
dividing. Monoclonal antibodies, such as bevacizumab, can block tumor growth in different
ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and
help kill them or carry tumor-killing substances to them. Bevacizumab may also stop the
growth of non-small cell lung cancer by blocking blood flow to the tumor. Pemetrexed disodium
may stop the growth of tumor cells by blocking some enzymes needed for cell growth. It is not
yet known whether giving bevacizumab or pemetrexed disodium alone or in combination is more
effective in treating non-squamous non-small cell lung cancer.
PURPOSE: This randomized phase III trial is studying bevacizumab and pemetrexed disodium
alone or in combination after induction therapy to see how well they work in treating
patients with advanced non-squamous non-small cell lung cancer.
Stanford is currently not accepting patients for this trial.
For more information, please contact Lisa Zhou, 6507364112.
Stanford Investigators
View full details
-
A Study of Pharmacokinetic Drug Interaction Study of the Hedgehog Pathway Inhibitor GDC-0449 in Combination With Rosiglitazone or Combined Oral Contraceptive in Patients With Locally Advanced or Metastatic Solid Tumors That Are Refractory to Standard Therapy or for Whom No Standard Therapy Exists
Not Recruiting
More
This is a single-arm, multicenter, Phase Ib study designed to describe the effect of GDC-0449
on the pharmacokinetics of rosiglitazone and oral contraceptives in patients with advanced
solid tumors who are refractory to treatment or for whom no standard therapy exists.
Stanford is currently not accepting patients for this trial.
For more information, please contact Ruth Lira, 6507231367.
Stanford Investigators
View full details
-
Evaluation of Cyberknife Precision Radiation Delivery System for Unresectable Malignant Lung Cancer
Not Recruiting
More
This study has two primary objectives. The first objective is to determine the maximal
tolerated dose (MTD) that can be delivered with stereotactic radiosurgery in patients with
inoperable malignant lung tumors. Once the MTD is established, the second objective is to
determine the efficacy of radiosurgical ablation of lung tumors in terms of symptoms and
radiographic responses.
Stanford is currently not accepting patients for this trial.
For more information, please contact Lisa Zhou, 6507364112.
Lead Sponsor
Stanford Investigators
View full details
-
Identification of Circulating Tumor Cells in the Peripheral Blood of Lung Cancer Patients
Not Recruiting
More
The primary aim of this study is to determine whether we can identify human lung cancer tumor
cells in the peripheral blood of lung cancer patients.
Stanford is currently not accepting patients for this trial.
For more information, please contact Lisa Zhou, 650-736-4112.
Lead Sponsor
Stanford Investigators
View full details
-
A Study of ASA404 or Placebo in Combination With Docetaxel in Second-line Treatment for (Stage IIIb/IV) Non-small Cell Lung Cancer
Not Recruiting
More
The purpose of this study is to determine if adding ASA404 to docetaxel chemotherapy makes
the cancer treatment more effective in patients with locally advanced or metastatic non-small
cell lung cancer
Stanford is currently not accepting patients for this trial.
For more information, please contact Melanie San Pedro-Salcedo, 6507241388.
Stanford Investigators
View full details
-
A Phase 2 Study of Amrubicin in Relapsed or Refractory Thymic Malignancies
Not Recruiting
More
A research study of the drug amrubicin in patients with cancer of the thymus (thymoma or
thymic carcinoma). We hope to learn whether this drug is an effective and safe treatment for
thymic cancers.
Stanford is currently not accepting patients for this trial.
For more information, please contact Melanie San Pedro-Salcedo, 650-724-1388.
Stanford Investigators
View full details
-
A Study of XL184 (Cabozantinib) With or Without Erlotinib in Adults With Non-Small Cell Lung Cancer
Not Recruiting
More
In Phase 1 of this study, the purpose is to evaluate the safety, tolerability, and highest
safe dose of the multiple receptor tyrosine kinase inhibitor (including VEGFR2, MET, and RET)
XL184 in combination with the EGFR inhibitor erlotinib administered to adults with
Non-Small-Cell Lung Cancer (NSCLC). In Phase 2 of this study, the purpose is to evaluate the
objective response rate of daily oral administration of XL184 with or without erlotinib in
subjects with NSCLC who have progressed after responding to treatment with erlotinib.
Stanford is currently not accepting patients for this trial.
For more information, please contact Lisa Zhou, 6507364112.
Stanford Investigators
View full details
-
An Investigational Drug, PF-02341066, Is Being Studied In Patients With Advanced Non-Small Cell Lung Cancer With A Specific Gene Profile Involving The Anaplastic Lymphoma Kinase (ALK) Gene
Not Recruiting
More
This is a Phase 2 trial that will evaluate the safety and efficacy of PF-02341066 in patients
with advanced non-small cell lung cancer with a specific gene profile involving the ALK gene.
This trial will also allow patients from a Phase 3 trial who received standard of care
chemotherapy (Study A8081007) to receive PF-02341066.
Stanford is currently not accepting patients for this trial.
For more information, please contact Melanie San Pedro-Salcedo, 6507241388.
Stanford Investigators
View full details
-
Phase I Vorinostat Concurrent With Stereotactic Radiosurgery (SRS) in Brain Metastases From Non-Small Cell Lung Cancer
Not Recruiting
More
The purpose of this study is to determine the maximum tolerated dose (MTD) of vorinostat
given concurrently with stereotactic radiosurgery (SRS) to treat non-small cell lung cancer
(NSCLCA) brain metastases in patient with 1-4 lesions.
Stanford is currently not accepting patients for this trial.
For more information, please contact Maria Coburn, 6507369551.
Lead Sponsor
Stanford Investigators
View full details
-
Phase 1/1b Study to Evaluate the Safety and Tolerability of Ciforadenant Alone and in Combination With Atezolizumab in Advanced Cancers
Not Recruiting
More
This is a phase 1/1b open-label, multicenter, dose-selection study of ciforadenant, an oral
small molecule targeting the adenosine-A2A receptor on T-lymphocytes and other cells of the
immune system. This trial will study the safety, tolerability, and anti-tumor activity of
ciforadenant as a single agent and in combination with atezolizumab, a PD-L1 inhibitor
against various solid tumors. Ciforadenant blocks adenosine from binding to the A2A receptor.
Adenosine suppresses the anti-tumor activity of T cells and other immune cells.
Stanford is currently not accepting patients for this trial.
For more information, please contact Cancer Clinical Trials Office (CCTO), 650-498-7061.
Stanford Investigators
View full details
-
4D-CT-based Ventilation Imaging for Adaptive Functional Guidance in Radiotherapy
Not Recruiting
More
To develop and investigate a novel radiotherapy technique for preserving lung function based
on a map of lung function.
Stanford is currently not accepting patients for this trial.
For more information, please contact Laura Gable, 650-736-0798.
Stanford Investigators
View full details
-
Radical-Dose Image Guided Radiation Therapy in Treating Patients With Metastatic Non-small Cell Lung Cancer Undergoing Immunotherapy
Not Recruiting
More
This phase II trial studies how well radical-dose image guided radiation therapy works in
treating patients with non-small cell lung cancer that has spread to other places in the body
who are undergoing immunotherapy. Radiation therapy uses high energy x-rays to kill tumor
cells and shrink tumors. Giving radical-dose image guided radiation therapy to patients with
non-small cell lung cancer may help to improve response to immunotherapy anti-cancer
treatment.
Stanford is currently not accepting patients for this trial.
For more information, please contact Kim Nguyen, 650-497-8966.
Lead Sponsor
Stanford Investigators
View full details
-
Sorafenib in Treating Patients With Refractory Non-Small Cell Lung Cancer
Not Recruiting
More
RATIONALE: Preclinical studies indicate that sorafenib is a potent inhibitor of Raf kinase in
vitro and in vivo, with significant dose-dependent, anti-tumor activity in four different
human tumor types including colon, pancreatic, lung, and ovarian. This activity was
cytostatic in nature and was maintained if dosing was continued. That is, tumor growth is
suspended while the drug is administered but returns to baseline rates when the agent is
withdrawn. Therefore, the optimal schedule will be an uninterrupted one. To assess the
activity of sorafenib in a timely manner and with a meaningful interpretation, a randomized
discontinuation design was adopted in the present trial, conducted in a population who were
potentially sensitive to sorafenib.
PURPOSE: This randomized phase II trial is studying sorafenib to see how well it works
compared to placebo in treating patients with refractory non-small cell lung cancer.
Stanford is currently not accepting patients for this trial.
For more information, please contact Lisa Zhou, 6507364112.
Stanford Investigators
View full details
-
Oxaliplatin, Leucovorin Calcium, and Fluorouracil With or Without Celecoxib in Treating Patients With Stage III Colon Cancer Previously Treated With Surgery
Not Recruiting
More
PURPOSE: This randomized phase III trial is studying giving oxaliplatin, leucovorin calcium,
and fluorouracil together to compare how well they work when given together with or without
celecoxib in treating patients with stage III colon cancer previously treated with surgery.
RATIONALE: Drugs used in chemotherapy, such as oxaliplatin, leucovorin calcium, and
fluorouracil, work in different ways to stop the growth of tumor cells, either by killing the
cells or by stopping them from dividing. Celecoxib may stop the growth of tumor cells by
blocking some of the enzymes needed for cell growth. It is not yet known whether giving
oxaliplatin, leucovorin calcium, and fluorouracil is more effective with or without celecoxib
in treating colon cancer.
Stanford is currently not accepting patients for this trial.
For more information, please contact Ben Priestley, 650-723-2990 (Palo Alto and South Bay locations).
Stanford Investigators
View full details
-
BLP25 Liposome Vaccine and Bevacizumab After Chemotherapy and Radiation Therapy in Treating Patients With Newly Diagnosed Stage IIIA or Stage IIIB Non-Small Cell Lung Cancer That Cannot Be Removed by Surgery
Not Recruiting
More
RATIONALE: Vaccines may help the body build an effective immune response to kill tumor cells.
Monoclonal antibodies, such as bevacizumab, can block tumor growth in different ways. Some
block the ability of tumor cells to grow and spread. Others find tumor cells and help kill
them or carry tumor-killing substances to them. Drugs used in chemotherapy work in different
ways to stop the growth of tumor cells, either by killing the cells or by stopping them from
dividing. Radiation therapy uses high-energy x-rays to kill tumor cells. Giving vaccine
therapy together with bevacizumab after chemotherapy and radiation therapy may kill more
tumor cells.
PURPOSE: This phase II trial is studying the side effects of giving BLP25 liposome vaccine
together with bevacizumab after chemotherapy and radiation therapy in treating patients with
newly diagnosed stage IIIA or stage IIIB non-small cell lung cancer that cannot be removed by
surgery.
Stanford is currently not accepting patients for this trial.
For more information, please contact Maria Pitsiouni, 650-721-6977.
Stanford Investigators
View full details
-
Cetuximab, Cisplatin, Fluorouracil, and Radiation Therapy in Treating Patients With Anal Cancer
Not Recruiting
More
RATIONALE: Monoclonal antibodies, such as cetuximab, can block tumor growth in different
ways. Some find tumor cells and kill them or carry tumor-killing substances to them. Others
interfere with the ability of tumor cells to grow and spread. Drugs used in chemotherapy,
such as cisplatin and fluorouracil, work in different ways to stop the growth of tumor cells,
either by killing the cells or by stopping them from dividing. Radiation therapy uses
high-energy x-rays to kill tumor cells. Cetuximab may help cisplatin and fluorouracil work
better by making tumor cells more sensitive to the drugs. It may also make tumor cells more
sensitive to radiation therapy. Giving cetuximab together with chemotherapy and radiation
therapy may kill more tumor cells.
PURPOSE: This phase II trial is studying how well giving cetuximab together with cisplatin,
fluorouracil, and radiation therapy works in treating immunocompetent patients with stage I
(closed to accrual as of 11/3/2008), stage II, (some stage II closed to accrual as of
11/3/2008) or stage III anal cancer.
Stanford is currently not accepting patients for this trial.
For more information, please contact Deryn Warner, 6507232876.
Stanford Investigators
View full details
-
Phase 1-2 of Temozolomide and Hypofractionated Radiotherapy in Tx of Supratentorial Glioblastoma Multiform
Not Recruiting
More
The purpose of this study is to investigate the safety and effectiveness of a combination
treatment for glioblastoma multiforme utilizing radiotherapy plus the FDA-approved
chemotherapy drug temozolomide
Stanford is currently not accepting patients for this trial.
For more information, please contact Polly Young, 650-497-7499.
Lead Sponsor
Stanford Investigators
View full details
-
ExAblate (MRgFUS) Treatment of Metastatic Bone Tumors for the Palliation of Pain
Not Recruiting
More
A Pivotal Study to Evaluate the Effectiveness and Safety of ExAblate Treatment of Metastatic
Bone and Multiple Myeloma Tumors for the Palliation of Pain in Patients Who are not
Candidates for Radiation Therapy
Stanford is currently not accepting patients for this trial.
For more information, please contact Kamil Unver, 6507259810.
Stanford Investigators
- Heather Wakelee
- Gloria Hwang, MD
- David Hovsepian, MD
- John D. Louie, MD
- Pejman Ghanouni, MD, PhD
- Daniel Sze, MD, PhD
- WILLIAM T. KUO, MD, FSIR, FCCP, FSVM, FACR, FCIRSE
- Nishita Kothary, MD
View full details
-
Clinical and Pathologic Studies of Patients Undergoing Treatment With EGFR Inhibitors
Not Recruiting
More
Cetuximab, erlotinib, and panitumumab are all recently FDA approved epidermal growth factor
receptor (EGFR) inhibitors that treat a wide variety of tumor types, such as colon, lung, and
head and neck. Blockade of the EGFR results in inhibition of multiple downstream pathways,
leading to slowed tumor growth. In addition, these inhibitors may enhance anti-tumor immune
responses through uncharacterized mechanisms. While producing significant responses in many
settings, EGFR inhibitors also result in significant skin toxicity (rash) in a high
percentage of patients. Multiple studies have correlated the presence and severity of rash
with clinical response. Unfortunately, severe rash can often lead to dose delays, reductions,
or even discontinuation of EGFR inhibitors, thus limiting their efficacy. The mechanism of
both the rash and its correlation with tumor response is poorly understood. Skin biopsies
display a robust leukocyte infiltrate, but a systematic analysis of the type of infiltrating
leukocytes, activation state, or homing receptor expression has not been performed.
Chemokines and chemokine receptors control leukocyte trafficking to the skin and other tissue
sites, and defined receptor profiles for skin-, gut-, and lung-homing leukocytes are well
established. In this study, the investigators propose to evaluate the homing phenotype of
leukocytes from peripheral blood and skin biopsies of patients receiving EGFR inhibitors. The
investigators will use RNA microarrays to evaluate the expression of chemokines and other key
genes regulated in skin during treatment. The investigators will utilize in vitro methods to
investigate effects of EGFR inhibitors on imprinting of T cell tissue-specific homing
receptors. The investigators will examine correlations among the pathologic data, clinical
findings, and tumor response. If validated, peripheral blood evaluation could potentially be
used as a predictive indicator for patients receiving EGFR inhibitors. This study may also
identify novel targets for limiting skin toxicity while receiving EGFR inhibitors, thus
allowing maximal dosing and clinical response from these agents.
Stanford is currently not accepting patients for this trial.
For more information, please contact Russell Pachynski, 6509066530.
Lead Sponsor
Stanford Investigators
View full details
-
CyberKnife Radiosurgical Treatment of Inoperable Early Stage Non-Small Cell Lung Cancer
Not Recruiting
More
The purpose of this study is to assess the short and long-term outcomes after CyberKnife
stereotactic radiosurgery for early stage non-small cell lung cancer (NSCLC) in patients who
are medically inoperable.
Stanford is currently not accepting patients for this trial.
For more information, please contact Lisa Zhou, 6507364112.
Stanford Investigators
View full details
-
Standard-Dose Combination Chemotherapy or High-Dose Combination Chemotherapy and Stem Cell Transplant in Treating Patients With Relapsed or Refractory Germ Cell Tumors
Not Recruiting
More
This randomized phase III trial studies how well standard-dose combination chemotherapy works
compared to high-dose combination chemotherapy and stem cell transplant in treating patients
with germ cell tumors that have returned after a period of improvement or did not respond to
treatment. Drugs used in chemotherapy, such as paclitaxel, ifosfamide, cisplatin,
carboplatin, and etoposide, work in different ways to stop the growth of tumor cells, either
by killing the cells, by stopping them from dividing, or by stopping them from spreading.
Giving chemotherapy before a stem cell transplant stops the growth of cancer cells by
stopping them from dividing or killing them. Giving colony-stimulating factors, such as
filgrastim or pegfilgrastim, and certain chemotherapy drugs, helps stem cells move from the
bone marrow to the blood so they can be collected and stored. Chemotherapy is then given to
prepare the bone marrow for the stem cell transplant. The stem cells are then returned to the
patient to replace the blood-forming cells that were destroyed by the chemotherapy. It is not
yet known whether high-dose combination chemotherapy and stem cell transplant are more
effective than standard-dose combination chemotherapy in treating patients with refractory or
relapsed germ cell tumors.
Stanford is currently not accepting patients for this trial.
For more information, please contact Cancer Clinical Trials Office (CCTO), 650-498-7061.
Stanford Investigators
View full details
-
Manuka Honey in Preventing Esophagitis-Related Pain in Patients Receiving Chemotherapy and Radiation Therapy For Lung Cancer
Not Recruiting
More
RATIONALE: Manuka honey may prevent or reduce esophagitis-related pain caused by chemotherapy
and radiation therapy. It is not yet known whether Manuka honey is more effective than
standard care in preventing pain.
PURPOSE: This randomized phase II clinical trial is studying Manuka honey to see how well it
works in preventing esophagitis-related pain in patients receiving chemotherapy and radiation
therapy for lung cancer.
Stanford is currently not accepting patients for this trial.
For more information, please contact Laura Gable, 6507360798.
Stanford Investigators
View full details
-
Carboplatin and Paclitaxel Combined With Cetuximab and/or IMC-A12 in Patients With Advanced Non-Small Cell Lung Cancer
Not Recruiting
More
This randomized phase II trial is studying how well giving carboplatin and paclitaxel
together with cetuximab and/or cixutumumab (IMC-A12) works in treating patients with stage
IIIB or stage IV non-small cell lung cancer. Drugs used in chemotherapy, such as carboplatin
and paclitaxel, work in different ways to stop the growth of tumor cells, either by killing
the cells or by stopping them from dividing. Monoclonal antibodies, such as cetuximab and
cixutumumab, can block tumor growth in different ways. Some block the ability of tumor cells
to grow and spread. Others find tumor cells and help kill them or carry tumor-killing
substances to them. Giving chemotherapy together with monoclonal antibody therapy may kill
more tumor cells. It is not yet known whether carboplatin and paclitaxel are more effective
when given with cetuximab and/or cixutumumab in treating non-small cell lung cancer.
Stanford is currently not accepting patients for this trial.
For more information, please contact Lauren Pernicka, 6507216977.
Stanford Investigators
View full details
-
Radiation Therapy Regimens in Treating Patients With Limited-Stage Small Cell Lung Cancer Receiving Cisplatin and Etoposide
Not Recruiting
More
Radiation therapy uses high-energy x-rays to kill tumor cells. Drugs used in chemotherapy,
such as etoposide, carboplatin and cisplatin, work in different ways to stop the growth of
tumor cells, either by killing the cells or by stopping them from dividing. It is not yet
known which radiation therapy regimen is more effective when given together with chemotherapy
in treating patients with limited-stage small cell lung cancer. This randomized phase III
trial is comparing different chest radiation therapy regimens to see how well they work in
treating patients with limited-stage small cell lung cancer.
Stanford is currently not accepting patients for this trial.
For more information, please contact Katie Brown, 650-723-1423.
Stanford Investigators
View full details
-
Adjuvant Afatinib in Stage I-III NSCLC With EGFR Mutation
Not Recruiting
More
This research study is a Phase II clinical trial, which tests the safety and effectiveness of
an investigational drug to learn whether the drug works in treating a specific cancer.
"Investigational" means that the drug is still being studied. It also means that the FDA has
not yet approved afatinib for use in patients.
In this research study the investigators are looking to see if taking afatinib after surgery
works better when taken over a short period of time, compared to a long period of time.
Stanford is currently not accepting patients for this trial.
For more information, please contact Lisa Zhou, 650-736-4112.
Stanford Investigators
View full details
-
A Study of Atezolizumab in Participants With Programmed Death - Ligand 1 (PD-L1) Positive Locally Advanced or Metastatic Non-Small Cell Lung Cancer
Not Recruiting
More
This multicenter, single-arm study will evaluate the efficacy and safety of Atezolizumab in
participants with PD-L1-positive locally advanced or metastatic non-small cell lung cancer
(NSCLC). Participants will receive Atezolizumab 1200 milligrams (mg) intravenously every 3
weeks as long as participants are experiencing clinical benefit as assessed by the
investigator, that is , in the absence of unacceptable toxicity or symptomatic deterioration
attributed to disease progression.
Stanford is currently not accepting patients for this trial.
For more information, please contact Lisa Zhou, 650-736-4112.
Stanford Investigators
View full details
-
Study of XL647 Administered Orally Daily to Patients With Solid Tumors
Not Recruiting
More
The purpose of this study is to assess the safety and tolerability of the multiple receptor
tyrosine kinase (RTK) inhibitor (including EGFR, VEGFR2, ErbB2, and EphB4) XL647 when given
orally daily to adults with advanced solid tumors.
Stanford is currently not accepting patients for this trial.
For more information, please contact Joanne Fehling, 6507361694.
Stanford Investigators
View full details
-
Phase 1 Trial of Oral Ixabepilone
Not Recruiting
More
This Phase 1 study of oral ixabepilone given every 6 hours for 3 doses on Day 1, every 21
days, was a dose-finding study designed to determine the maximum tolerated dose (MTD) and
safety of this dosing schedule in participants with advanced cancer
Stanford is currently not accepting patients for this trial.
For more information, please contact Dana Supan, 6507361694.
Stanford Investigators
View full details
-
Paclitaxel With or Without Cixutumumab as Second-Line Therapy in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer
Not Recruiting
More
This randomized phase II trial studies how well paclitaxel with or without cixutumumab works
in treating patients with esophageal cancer or gastroesophageal junction cancer that has
spread to other places in the body (metastatic). Drugs used in chemotherapy, such as
paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the
cells, by stopping them from dividing, or by stopping them from spreading. Cixutumumab may
kill cancer cells by blocking the action of a protein needed for cancer cell growth. Giving
paclitaxel with or without cixutumumab may kill more tumor cells.
Stanford is currently not accepting patients for this trial.
For more information, please contact Deryn Warner, 6507232876.
Stanford Investigators
View full details
-
Study of Cobimetinib in Participants With Solid Tumors
Not Recruiting
More
This non-randomized, open-label, study will determine the highest safe dose of cobimetinib,
how often it should be taken, how well participants with cancer tolerate cobimetinib and will
assess the pharmacokinetic effect of midazolam and dextromethorphan on the study drug.
Stanford is currently not accepting patients for this trial.
For more information, please contact Dana Supan, 6507361694.
Stanford Investigators
View full details
-
Randomized Study to Compare CyberKnife to Surgical Resection In Stage I Non-small Cell Lung Cancer
Not Recruiting
More
Lung cancer remains the most frequent cause of cancer death in both men and women in the
world. Surgical resection using lobectomy with mediastinal lymph node dissection or sampling
has been a standard of care for operable early stage NSCLC. Several studies have reported
high local control and survival using SBRT in stage I NSCLC patients. SBRT is now an accepted
treatment for medically inoperable patients with stage I NSCLC and patients with operable
stage I lung cancer are entered on clinical protocols. The purpose of this study is to
conduct a phase III randomized study to compare CyberKnife SBRT with surgery, the current
standard of care for stage I operable NSCLC.
Stanford is currently not accepting patients for this trial.
For more information, please contact Lisa Zhou, 6507364112.
Stanford Investigators
View full details
-
A Study of Onartuzumab (MetMAb) in Combination With Bevacizumab (Avastin) Plus Platinum And Paclitaxel or With Pemetrexed Plus Platinum in Patients With Non-Squamous Non-Small Cell Lung Cancer
Not Recruiting
More
This multicenter, randomized, double-blind, placebo-controlled study will evaluate the
efficacy and safety of RO5490258 (MetMab) in combination with either of two backbone
chemotherapy regimens in the first-line setting in patients with incurable Stage IIIB or IV
non-squamous non-small cell lung cancer. In Cohort 1, patients will be randomized to receive
4 cycles of bevacizumab (Avastin) 15 mg/kg iv, paclitaxel 200 mg/m2 iv, platinum
(cisplatin/carboplatin) iv plus either MetMab 15 mg/kg iv or placebo on Day 1 of each 21-day
cycle. In Cohort 2, patients will be randomized to receive pemetrexed 500 mg/m2 iv, platinum
(cisplatin/carboplatin) iv plus either MetMAb 15 mg/m2 iv or placebo on Day 1 of each 21-day
cycle. Patients who have not progressed after 4 cycles will be offered maintenance therapy
with their assigned treatment of bevacizumab plus either MetMAb or placebo (Cohort 1) or
pemetrexed plus either MetMAb or placebo (Cohort 2). Anticipated time on study treatment is
until disease progression or unacceptable toxicity occurs.
Stanford is currently not accepting patients for this trial.
For more information, please contact Melanie SanPedro-Salcedo, 6507241388.
Stanford Investigators
View full details
-
Screening Protocol for Tumor Antigen Expression Profiling and HLA Typing for Eligibility Determination
Not Recruiting
More
This screening study is intended for men and women ≥ 18 to ≤ 75 years of age who have
advanced solid or hematologic malignancy. The study will assess a subject's human leukocyte
antigen (HLA) subtype and tumor antigen expression profile. Based on the results, it will be
determined if a subject is eligible to be considered for Adaptimmune sponsored clinical
trials testing the safety and efficacy of genetically changed T cells targeting specific
tumor antigens. No treatment intervention will occur as part of this screening study.
Upon enrollment, subjects will be required to provide a blood sample for HLA subtype
analysis. If the results of the analysis match the HLA-A subtypes noted in the inclusion
criteria and do not express the HLA subtypes that are exclusionary for the available
interventional clinical trial(s), then the subject will be required to provide either an
archival tumor specimen or fresh tumor tissue biopsy. The tumor specimen will be screened at
a central laboratory for the expression (protein or gene) of multiple antigens which may
include, but are not limited to MAGE-A4. Based upon the results of these diagnostic analyses,
if eligible, subjects will be referred to an appropriate available interventional clinical
trial(s) at the discretion of the Investigator.
Following screening, tumor samples will be retained by Adaptimmune for the purpose of
developing and validating in vitro diagnostic (IVD) assay(s) for antigen expression profiling
which is required for regulatory approval of a new therapeutic product indication.
Stanford is currently not accepting patients for this trial.
For more information, please contact Cancer Clinical Trials Office (CCTO), 650-498-7061.
Stanford Investigators
View full details
-
Study to Assess Safety and Efficacy of Atezolizumab (MPDL3280A) Compared to Best Supportive Care Following Chemotherapy in Patients With Lung Cancer [IMpower010]
Not Recruiting
More
This is a Phase III, global, multicenter, open-label, randomized study to compare the
efficacy and safety of 16 cycles (1 cycle duration=21 days) of atezolizumab (MPDL3280A)
treatment compared with best supportive care (BSC) in participants with Stage IB-Stage IIIA
non-small cell lung cancer (NSCLC) following resection and adjuvant chemotherapy, as measured
by disease-free survival (DFS) as assessed by the investigator and overall survival (OS).
Participants, after completing up to 4 cycles of adjuvant cisplatin-based chemotherapy, will
be randomized in a 1:1 ratio to receive atezolizumab for 16 cycles or BSC.
Stanford is currently not accepting patients for this trial.
For more information, please contact Cancer Clinical Trials Office (CCTO), 650-498-7061.
Stanford Investigators
View full details
-
Phase 2a Desipramine in Small Cell Lung Cancer and Other High-Grade Neuroendocrine Tumors
Not Recruiting
More
Intrapatient dose escalation study of desipramine in subjects with small cell lung cancer
(SCLC) and other high-grade neuroendocrine tumors.
Stanford is currently not accepting patients for this trial.
For more information, please contact CCTO, 650-498-7061.
Stanford Investigators
View full details
-
A Study of TAK-788 in Adults With Non-Small Cell Lung Cancer
Recruiting
More
This study is about a medicine called TAK-788, also known as mobocertinib, given to adults
with non-small cell lung cancer. The main aims of this study are to check if there are any
side effects from TAK-788, to learn how TAK-788 is processed by the body, and to determine
the best dose of TAK-788 to treat this condition. Participants will take TAK-788 capsules
with chemotherapy. Participants will continue to take TAK-788 unless they or their doctor
decide they should stop this treatment. Participants will take TAK-788 capsules with or
without chemotherapy under antidiarrhea prevention to determine the safety of TAK-788
treatment. Non-Asian, non-White participants will take TAK-788 to determine the safety and
tolerability of TAK-788 treatment.
Stanford Investigators
View full details
-
Phase II Docetaxel / Carboplatin / XRT + Surgical Resection in Stage III NSCLC
Not Recruiting
More
The purpose of this study is to assess how well this particular combination of chemotherapy,
radiation and surgery works to help people with locally advanced lung cancer, how well PET
scans indicates whether someone has responded to chemotherapy and radiation, and gene
expression patterns related to outcomes in patients with locally advanced lung cancer who
receive this treatment regimen.
Stanford is currently not accepting patients for this trial.
For more information, please contact Lisa Zhou, 6507364112.
Lead Sponsor
Stanford Investigators
View full details
-
Safety and Tolerability Study of SNS-314 for Advanced Solid Tumors
Not Recruiting
More
This is a study to assess the safety and tolerability of SNS-314 in advanced solid tumors in
humans.
Stanford is currently not accepting patients for this trial.
For more information, please contact Sipra Choudhury, 6507362563.
Stanford Investigators
View full details
-
Pulmonary Interstitial Lymphography in Early Stage Lung Cancer
Not Recruiting
More
The stereotactic body radiation therapy (SBRT) procedure is an emerging alternative to the
standard treatment for early stage non-small cell lung cancer (NSCLC), typically lobectomy
with lymphadenectomy. This procedure (lobectomy) does not fulfill the medical need as many
patients are poor operative candidates or decline surgery.
This study assesses the feasibility of stereotactic body radiation therapy (SBRT) as a tool
to produce therapeutically useful computed tomography (CT) scans, using standard
water-soluble iodinated compounds as the contrast agents.
Stanford is currently not accepting patients for this trial.
For more information, please contact Laura Gable, 6507360798.
Lead Sponsor
Stanford Investigators
View full details
-
Bendamustine Hydrochloride and Rituximab With or Without Bortezomib Followed by Rituximab With or Without Lenalidomide in Treating Patients With High-Risk Stage II, Stage III, or Stage IV Follicular Lymphoma
Not Recruiting
More
RATIONALE: Drugs used in chemotherapy, such as bendamustine hydrochloride, work in different
ways to stop the growth of cancer cells, either by killing the cells or by stopping them from
dividing. Monoclonal antibodies, such as rituximab, can block cancer growth in different
ways. Some block the ability of cancer cells to grow and spread. Others find cancer cells and
help kill them or carry cancer-killing substances to them. Bortezomib may stop the growth of
cancer cells by blocking some of the enzymes needed for cell growth. Biological therapies,
such as lenalidomide, may stimulate the immune system in different ways and stop cancer cells
from growing. It is not yet known whether giving bendamustine hydrochloride and rituximab
together alone is more effective than giving bendamustine hydrochloride and rituximab
together with bortezomib or lenalidomide in treating follicular lymphoma.
PURPOSE: This randomized phase II trial is studying giving bendamustine hydrochloride and
rituximab together with or without bortezomib followed by rituximab with or without
lenalidomide to see how well they work in treating patients with high-risk stage II, stage
III, or stage IV follicular lymphoma.
Stanford is currently not accepting patients for this trial.
For more information, please contact Ekaterina Dib, 650-723-0503.
Stanford Investigators
View full details
-
Saracatinib in Treating Patients With Relapsed or Refractory Thymoma or Thymic Cancer
Not Recruiting
More
This phase II trial is studying how well saracatinib works in treating patients with relapsed
or refractory thymoma or thymic cancer. Saracatinib may stop the growth of tumor cells by
blocking some of the enzymes needed for cell growth
Stanford is currently not accepting patients for this trial.
For more information, please contact Melanie San Pedro-Salcedo, 6507241388.
Stanford Investigators
View full details
-
Molecular Analysis of Thoracic Malignancies
Recruiting
More
A research study to learn about the biologic features of cancer development, growth, and
spread. We are studying components of blood, tumor tissue, normal tissue, and other fluids,
such as urine, cerebrospinal fluid, abdominal or chest fluid in patients with cancer. Our
analyses of blood, tissue, and/or fluids may lead to improved diagnosis and treatment of
cancer by the identification of markers that predict clinical outcome, markers that predict
response to specific therapies, and the identification of targets for new therapies.
Lead Sponsor
Stanford Investigators
View full details
-
Genetic Testing in Screening Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been or Will Be Removed by Surgery (The ALCHEMIST Screening Trial)
Recruiting
More
This ALCHEMIST trial studies genetic testing in screening patients with stage IB-IIIA
non-small cell lung cancer that has been or will be removed by surgery. Studying the genes in
a patient's tumor cells may help doctors select the best treatment for patients that have
certain genetic changes.
Stanford Investigators
View full details
-
Lung-MAP: Nivolumab With or Without Ipilimumab as Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer and No Matching Biomarkers
Not Recruiting
More
This randomized phase III trial compares nivolumab with ipilimumab and nivolumab alone in
treating patients with stage IV squamous cell lung cancer that has come back after previous
treatment. This is a "non-match" sub-study that includes all screened patients not eligible
for a biomarker-driven sub-study. Monoclonal antibodies, such as nivolumab and ipilimumab,
may be able to shrink tumors. It is not yet known whether nivolumab works better with or
without ipilimumab in treating patients with squamous cell lung cancer.
Stanford is currently not accepting patients for this trial.
For more information, please contact Heather A. Wakelee, 650-498-7061.
Stanford Investigators
View full details
-
Erlotinib Hydrochloride in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Completely Removed by Surgery (An ALCHEMIST Treatment Trial)
Not Recruiting
More
This phase III ALCHEMIST trial studies how well erlotinib hydrochloride compared to
observation works in treating patients with stage IB-IIIA non-small cell lung cancer that has
been completely removed by surgery (resected). Erlotinib hydrochloride may stop the growth of
tumor cells by blocking some of the enzymes needed for cell growth.
Stanford is currently not accepting patients for this trial.
For more information, please contact Heather A. Wakelee, 650-724-3697.
Stanford Investigators
View full details
-
Study of Positron Emission Tomography and Computed Tomography in Guiding Radiation Therapy in Patients With Stage III Non-small Cell Lung Cancer
Not Recruiting
More
This randomized phase II trial studies how well positron emission tomography (PET)/computed
tomography (CT)-guided radiation therapy works compared to standard radiation therapy in
treating patients with stage III non-small cell lung cancer. Radiation therapy uses
high-energy x-rays to kill tumor cells. Using imaging procedures, such as PET and CT scans,
to guide the radiation therapy, may help doctors deliver higher doses directly to the tumor
and cause less damage to healthy tissue.
Stanford is currently not accepting patients for this trial.
For more information, please contact Laura Gable, 650-736-0798.
Stanford Investigators
View full details
-
Lung-MAP: Biomarker-Targeted Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer
Not Recruiting
More
This screening and multi-sub-study randomized phase II/III trial will establish a method for
genomic screening of similar large cancer populations followed by assigning and accruing
simultaneously to a multi-sub-study hybrid ?Master Protocol? (S1400). The type of cancer
trait (biomarker) will determine to which sub-study, within this protocol, a participant will
be assigned to compare new targeted cancer therapy, designed to block the growth and spread
of cancer, or combinations to standard of care therapy with the ultimate goal of being able
to approve new targeted therapies in this setting. In addition, the protocol includes a
?non-match? sub-study which will include all screened patients not eligible for any of the
biomarker-driven sub-studies. This sub-study will compare a non-match therapy to standard of
care also with the goal of approval.
Stanford is currently not accepting patients for this trial.
For more information, please contact Cancer Clinical Trials Office (CCTO), 650-498-7061.
Stanford Investigators
View full details
-
Crizotinib in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Removed by Surgery and ALK Fusion Mutations (An ALCHEMIST Treatment Trial)
Recruiting
More
This randomized phase III trial studies how well crizotinib works in treating patients with
stage IB-IIIA non-small cell lung cancer that has been removed by surgery and has a mutation
in a protein called anaplastic lymphoma kinase (ALK). Mutations, or changes, in ALK can make
it very active and important for tumor cell growth and progression. Crizotinib may stop the
growth of tumor cells by blocking the ALK protein from working. Crizotinib may be an
effective treatment for patients with non-small cell lung cancer and an ALK fusion mutation.
Stanford Investigators
View full details
-
A Multi-Center Study of Ibrutinib in Combination With MEDI4736 in Subjects With Relapsed or Refractory Solid Tumors
Not Recruiting
More
This is a Phase 1b/2, multi-center study to assess the safety and efficacy of ibrutinib in
combination with durvalumab (MEDI4736) in participants with relapsed or refractory solid
tumors.
Stanford is currently not accepting patients for this trial.
For more information, please contact Cancer Clinical Trials Office (CCTO), 650-498-7061.
Stanford Investigators
View full details
-
Study of Atezolizumab in Combination With Cobimetinib in Participants With Locally Advanced or Metastatic Solid Tumors
Not Recruiting
More
This is a Phase Ib, open-label, multicenter study designed to assess the safety,
tolerability, and pharmacokinetics of coadministration of intravenous (IV) dosing of
atezolizumab (an engineered anti-programmed death-ligand 1 [anti-PD-L1] antibody) and oral
dosing of cobimetinib in participants with metastatic or locally advanced cancer for which no
standard therapy exists.
Stanford is currently not accepting patients for this trial.
For more information, please contact Lisa Zhou, 650-736-4112.
Stanford Investigators
View full details
-
TIGER-3: Open Label, Multicenter Study of Rociletinib (CO-1686) Mono Therapy Versus Single-agent Cytotoxic Chemotherapy in Patients With Mutant EGFR NSCLC Who Have Failed at Least One Previous EGFR-Directed TKI and Platinum-doublet Chemotherapy
Not Recruiting
More
The purpose of this study is to compare the anti-tumor efficacy of oral single-agent
rociletinib, as measured by investigator assessment of the PFS, with that of single-agent
cytotoxic chemotherapy in patients with EGFR-mutated, advanced/metastatic NSCLC after failure
of at least 1 previous EGFR-directed TKI and at least 1 line of platinum-containing doublet
chemotherapy.
Stanford is currently not accepting patients for this trial.
For more information, please contact Melanie San Pedro-Salcedo, 650-724-1388.
Stanford Investigators
View full details
-
A Study Of PF-06647020 For Adult Patients With Advanced Solid Tumors
Not Recruiting
More
To assess the safety and tolerability at increasing dose levels of PF-06647020 in patients
with advanced solid tumors in order to determine the maximum tolerated dose and select the
recommended Phase 2 dose.
Stanford is currently not accepting patients for this trial.
For more information, please contact Cancer Clinical Trials Office (CCTO), 650-498-7061.
Stanford Investigators
View full details
-
Radiation Therapy in Treating Patients With Stage I Non-Small Cell Lung Cancer
Not Recruiting
More
RATIONALE: Radiation therapy uses high-energy x-rays to kill tumor cells. Specialized
radiation therapy that delivers a high dose of radiation directly to the tumor may kill more
tumor cells and cause less damage to normal tissue. It is not yet known which regimen of
stereotactic body radiation therapy is more effective in treating patients with non-small
cell lung cancer.
PURPOSE: This randomized phase II trial is studying the side effects of two radiation therapy
regimens and to see how well they work in treating patients with stage I non-small cell lung
cancer.
Stanford is currently not accepting patients for this trial.
For more information, please contact laura gable, 6507360798.
Stanford Investigators
View full details
-
Nivolumab After Surgery and Chemotherapy in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer (An ALCHEMIST Treatment Trial)
Not Recruiting
More
This phase III ALCHEMIST treatment trial studies how well nivolumab after surgery and
chemotherapy work in treating patients with stage IB-IIIA non-small cell lung cancer.
Immunotherapy with monoclonal antibodies, such as nivolumab, may help the body's immune
system attack the cancer, and may interfere with the ability of tumor cells to grow and
spread.
Stanford is currently not accepting patients for this trial.
For more information, please contact Cancer Clinical Trials Office (CCTO), 650-498-7061.
Stanford Investigators
View full details
-
A Dose Escalation and Cohort Expansion Study of NKTR-214 in Combination With Nivolumab and Other Anti-Cancer Therapies in Patients With Select Advanced Solid Tumors
Not Recruiting
More
In this four-part study, NKTR-214 was administered in combination with nivolumab and
with/without other anticancer therapies. Part 1 considered escalating doublet (NKTR 214 +
nivolumab) doses to determine the RP2D. Part 2 considered dose expansion cohorts for the
doublet (NKTR 214 + nivolumab ± chemotherapy). Part 3 was schedule-finding for a triplet
therapy (NKTR 214 + nivolumab + ipilimumab). Part 4 dose expansion for the triplet (NKTR 214
+ nivolumab + ipilimumab) was planned to further assess the efficacy of the RP2D triplet
combination at dosing schedules from Part 3.
Stanford is currently not accepting patients for this trial.
For more information, please contact Cancer Clinical Trials Office (CCTO), 650-498-7061.
Stanford Investigators
View full details
-
Pemetrexed Disodium/Observation in Treating Patients W/ Malignant Pleural Mesothelioma w/Out Progressive Disease After 1st Line Chemotherapy
Not Recruiting
More
RATIONALE: Pemetrexed disodium may stop the growth of tumor cells by blocking some of the
enzymes needed for cell growth.
PURPOSE: This randomized phase II trial is studying how well pemetrexed disodium or
observation works in treating patients with malignant pleural mesothelioma without
progressive disease after first-line chemotherapy.
Stanford is currently not accepting patients for this trial.
For more information, please contact Ekaterina Dib, 650-723-0503.
Stanford Investigators
View full details
-
Phase 1/2 Study of X-396, an Oral ALK Inhibitor, in Patients With ALK-positive Non-Small Cell Lung Cancer
Not Recruiting
More
This is the first human study to use X-396 (ensartinib), a drug being developed for treatment
of advanced cancers. The initial purpose of the study is to determine the largest amount of
X-396 that can be safely given to humans (the maximum tolerated dose). Once the recommended
Phase 2 dose has been determined, an expansion phase will assess the preliminary anti-tumor
activity of X-396 in ALK-positive non-small cell lung cancer. The study will also provide
early information on how the body handles the drug (pharmacokinetics) and on the efficacy of
X-396.
Stanford is currently not accepting patients for this trial.
For more information, please contact Melanie San Pedro-Salcedo, 650-724-1388.
Stanford Investigators
View full details
-
Pazopanib Hydrochloride in Treating Patients With Progressive Carcinoid Tumors
Not Recruiting
More
This randomized phase II trial studies how well pazopanib hydrochloride works in treating
patients with carcinoid tumors that are growing, spreading, or getting worse. Pazopanib
hydrochloride may stop the growth of tumor cells by blocking some of the enzymes needed for
cell growth.
Stanford is currently not accepting patients for this trial.
For more information, please contact Ben Priestley, 650-723-2990.
Stanford Investigators
View full details
-
An Open-Label, Randomized, Phase 3 Trial of Nivolumab Versus Investigator's Choice Chemotherapy as First-Line Therapy for Stage IV or Recurrent PD-L1+ Non-Small Cell Lung Cancer (CheckMate 026)
Not Recruiting
More
The purpose of this study is to show that Nivolumab will improve progression free survival in
subjects with strongly Stage IV or Recurrent PD-L1+ non-small cell lung cancer when compared
to chemotherapy
Stanford is currently not accepting patients for this trial.
For more information, please contact Smriti Rai, 650-723-0270.
Stanford Investigators
View full details
-
Recombinant Interleukin-15 in Treating Patients With Advanced Melanoma, Kidney Cancer, Non-small Cell Lung Cancer, or Squamous Cell Head and Neck Cancer
Not Recruiting
More
This phase I trial studies the side effects and best dose of recombinant interleukin-15 in
treating patients with melanoma, kidney cancer, non-small cell lung cancer, or head and neck
cancer that has spread to other places in the body and usually cannot be cured or controlled
with treatment. Recombinant interleukin-(IL)15 is a biological product, a protein, made
naturally in the body and when made in the laboratory may help stimulate the immune system in
different ways and stop tumor cells from growing.
Stanford is currently not accepting patients for this trial.
For more information, please contact Brenda Hann, 650-723-0966.
Stanford Investigators
View full details
-
A Phase 1/2 Study to Evaluate MEDI4736
Not Recruiting
More
This is a multicenter, open-label, first-time-in-human study with a standard 3+3
dose-escalation phase in participants with advanced solid tumors followed by an expansion
phase in participants with advanced solid tumors. An exploration cohort has been added to
determine the safety using every 4 weeks (Q4W) dosing.
Stanford is currently not accepting patients for this trial.
For more information, please contact Melanie San Pedro-Salcedo, 650-724-1388.
Stanford Investigators
View full details
-
Pembrolizumab in Patients With Metastatic Non-squamous Non-small Cell Lung Cancer
Not Recruiting
More
This phase II trial studies how well pembrolizumab works in treating patients with
non-squamous non-small cell lung cancer which has spread to other places in the body.
Monoclonal antibodies, such as pembrolizumab, may interfere with the ability of tumor cells
to grow and spread.
Stanford is currently not accepting patients for this trial.
For more information, please contact Richard Quick, 650-723-2983.
Stanford Investigators
View full details
-
Erlotinib Hydrochloride or Crizotinib and Chemoradiation Therapy in Treating Patients With Stage III Non-small Cell Lung Cancer
Not Recruiting
More
This randomized phase II trial studies how well erlotinib hydrochloride or crizotinib with
chemoradiation therapy works in treating patients with stage III non-small cell lung cancer.
Radiation therapy uses high energy x rays to kill tumor cells. Specialized radiation therapy
that delivers a high dose of radiation directly to the tumor may kill more tumor cells and
cause less damage to normal tissue. Drugs used in chemotherapy, such as cisplatin, etoposide,
paclitaxel, and carboplatin, work in different ways to stop the growth of tumor cells, either
by killing the cells, by stopping them from dividing, or by stopping them from spreading. It
is not yet known whether giving erlotinib hydrochloride is more effective than crizotinib
with chemoradiation therapy in treating patients with non-small cell lung cancer.
Stanford is currently not accepting patients for this trial.
For more information, please contact Katie Brown, 650-723-1423.
Stanford Investigators
View full details
-
Erlotinib and Momelotinib for the Treatment of Epidermal Growth Factor Receptor (EGFR) Mutated EGFR Tyrosine Kinase Inhibitor (TKI) Naive Metastatic Non-Small Cell Lung Cancer (NSCLC)
Not Recruiting
More
This study will evaluate the safety, preliminary efficacy, and pharmacokinetics (PK) of
momelotinib (MMB) and erlotinib, as well as define the maximum tolerated dose (MTD) of
momelotinib (MMB) combined with erlotinib in adults with epidermal growth factor receptor
(EGFR)-mutated, EGFR tyrosine kinase inhibitor (TKI) naive metastatic non-small cell lung
cancer (NSCLC). Participants will be sequentially enrolled to receive progressively
increasing doses of momelotinib (MMB) in combination with erlotinib. Escalation of
momelotinib (MMB) doses will proceed to the MTD, defined as the highest tested dose
associated with dose-limiting toxicities (DLT) during the first 28 days of combined erlotinib
and momelotinib (MMB) treatment. There will be four dose levels and each treatment cycle will
consist of 28 days.
Stanford is currently not accepting patients for this trial.
For more information, please contact Smriti Rai, 650-723-0270.
Stanford Investigators
View full details
-
Brentuximab Vedotin and Nivolumab With or Without Ipilimumab in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma
Not Recruiting
More
This phase I/II trial studies the side effects and best dose of ipilimumab and nivolumab when
given together with brentuximab vedotin, and how well they work in treating patients with
Hodgkin lymphoma that has returned after a period of improvement (recurrent) or has not
responded to previous treatment (refractory). Immunotherapy with monoclonal antibodies, such
as ipilimumab and nivolumab, may help the body's immune system attack the cancer, and may
interfere with the ability of cancer cells to grow and spread. Brentuximab vedotin is a
monoclonal antibody, brentuximab, linked to a toxic agent called vedotin. Brentuximab
attaches to CD30 positive cancer cells in a targeted way and delivers vedotin to kill them.
It is not known whether giving brentuximab vedotin and nivolumab with or without ipilimumab
may kill more cancer cells.
Stanford is currently not accepting patients for this trial.
For more information, please contact Caitlin Plahn, 650-723-3046.
Stanford Investigators
View full details
-
Study of the Glutaminase Inhibitor CB-839 in Solid Tumors
Not Recruiting
More
Many tumor cells, in contrast to normal cells, have been shown to require the amino acid
glutamine to produce energy for growth and survival. To exploit the dependence of tumors on
glutamine, CB-839, a potent and selective inhibitor of the first enzyme in glutamine
utilization, glutaminase, will be tested in this Phase 1 study in patients with solid tumors.
This study is an open-label Phase 1 evaluation of CB-839 in patients with advanced solid
tumors. The study will be conducted in 2 parts. Part 1 is a dose escalation study enrolling
patients with locally-advanced, metastatic and/or refractory solid tumors to receive CB-839
capsules orally twice or three times daily.
In Part 2, patients with each of the following diseases will be enrolled: A) Triple-Negative
Breast Cancer, B) Non-Small Cell Lung Cancer (adenocarcinoma), C) Renal Cell Cancer, D)
Mesothelioma, E) Fumarate hydratase (FH)-deficient tumors, F) Succinate dehydrogenase
(SDH)-deficient gastrointestinal stromal tumors (GIST), G) SDH-deficient non-GIST tumors, H)
tumors harboring mutations in isocitrate dehydrogenase-1 (IDH1) or IDH2, and I) cMyc mutation
tumors.
As an extension of Parts 1 & 2, patients will be treated with CB-839 in combination with
standard chemotherapy. Combination groups include: Pac-CB, CBE, CB-Erl, CBD, and CB-Cabo.
Pac-CB: patients with locally-advanced or metastatic TNBC will be treated with paclitaxel and
CB-839. CBE: patients with advanced clear cell RCC or papillary RCC will be treated with
everolimus in combination with CB-839. CB-Erl: patients with advanced NSCLC lacking the T790M
EGFR mutation will be treated with erlotinib and CB-839. CBD: patients with NSCLC harboring
KRAS mutation will be treated with docetaxel and CB-839. CB-Cabo: patients with
histologically confirmed diagnosis of locally-advanced, inoperable or metastatic RCC treated
with cabozantinib in combination with CB-839.
All patients will be assessed for safety, pharmacokinetics (plasma concentration of drug),
pharmacodynamics (inhibition of glutaminase), biomarkers (biochemical markers that may
predict responsiveness in later studies), and tumor response.
Stanford is currently not accepting patients for this trial.
For more information, please contact Pei-Jen Chang, 650-725-0866.
Stanford Investigators
View full details
-
Imaging and Biomarkers of Hypoxia in Solid Tumors
Not Recruiting
More
Hypoxia, meaning a lack of oxygen, has been associated strongly with a wide range of human
cancers. Hypoxia occurs when tumor growth exceeds the ability of blood vessels to supply the
tumor with oxygenated blood. It is currently understood that hypoxic tumors are more
aggressive. Current methods for measuring hypoxia include invasive procedures such as tissue
biopsy, or insertion of an electrode into the tumor. EF5-PET may be a non-invasive way to
measure tumor hypoxia.
Stanford is currently not accepting patients for this trial.
For more information, please contact Justin Carter, 650-725-4796.
Lead Sponsor
Stanford Investigators
- Heather Wakelee
- Quynh-Thu Le, MD
- Edward Graves
- John B. Sunwoo, MD
- Joseph Shrager
- Maximilian Diehn, MD, PhD
- Edward J. Damrose, MD, FACS
- Michael J. Kaplan, MD
- Amato J. Giaccia
- A. Dimitrios Colevas, MD
- Billy W Loo, Jr, MD PhD FASTRO FACR
View full details
-
18F-FPPRGD2 PET/CT or PET/MRI in Predicting Early Response in Patients With Cancer Receiving Anti-Angiogenesis Therapy
Not Recruiting
More
The purpose of the study is to conduct research of a new PET radiopharmaceutical in cancer
patients. The uptake of the novel radiopharmaceutical 18F-FPPRGD2 will be assessed in study
participants with glioblastoma multiforme (GBM), gynecological cancers, and renal cell
carcinoma (RCC) who are receiving antiangiogenesis treatment.
Stanford is currently not accepting patients for this trial.
For more information, please contact CCTO, 650-498-7061.
Stanford Investigators
View full details
-
Erlotinib Hydrochloride and Cabozantinib-s-Malate Alone or in Combination as Second or Third Line Therapy in Treating Patients With Stage IV Non-small Cell Lung Cancer
Not Recruiting
More
This randomized phase II trial studies how well giving erlotinib hydrochloride and
cabozantinib-s-malate alone or in combination works as second or third line therapy in
treating patient with stage IV non-small cell lung cancer. Erlotinib hydrochloride and
cabozantinib-s-malate may stop the growth of tumor cells by blocking some of the enzymes
needed for cell growth. It is not yet known whether giving erlotinib hydrochloride together
with cabozantinib-s-malate is more effective than erlotinib hydrochloride or
cabozantinib-s-malate alone in treating non-small cell lung cancer.
Stanford is currently not accepting patients for this trial.
For more information, please contact Maria Pitsiouni, 650-721-6977.
Stanford Investigators
View full details
-
PROSPECT: Chemotherapy Alone or Chemotherapy Plus Radiation Therapy in Treating Patients With Locally Advanced Rectal Cancer Undergoing Surgery
Not Recruiting
More
The standard treatment for locally advanced rectal cancer involves chemotherapy and
radiation, known as 5FUCMT, (the chemotherapy drugs 5-fluorouracil/capecitabine and radiation
therapy) prior to surgery. Although radiation therapy to the pelvis has been a standard and
important part of treatment for rectal cancer and has been shown to decrease the risk of the
cancer coming back in the same area in the pelvis, some patients experience undesirable side
effects from the radiation and there have been important advances in chemotherapy, surgery,
and radiation which may be of benefit. The purpose of this study is to compare the effects,
both good and bad, of the standard treatment of chemotherapy and radiation to chemotherapy
using a combination regimen known as FOLFOX, (the drugs 5-fluorouracil (5-FU), oxaliplatin
and leucovorin) and selective use of the standard treatment, depending on response to the
FOLFOX. The drugs in the FOLFOX regimen are all FDA (Food and Drug Administration) approved
and have been used routinely to treat patients with advanced colorectal cancer.
Stanford is currently not accepting patients for this trial.
For more information, please contact Ben Priestley, 650-723-2990.
Stanford Investigators
View full details
-
Expanded Treatment Protocol With LDK378 in ALK(+) NSCLC
Not Recruiting
More
Novartis-sponsored, open-label, multi-center, interventional ETP to provide LDK378 to
patients with ALK (+)NSCLC, who have been pre-treated with an ALK inhibitor; except in
countries where ALK inhibitors are not approved or available. The protocol will further
evaluate the safety of LDK378 in patients with ALK(+) NSCLC.
Stanford is currently not accepting patients for this trial.
For more information, please contact Melanie San Pedro-Salcedo, 650-724-1388.
Stanford Investigators
View full details
-
Transoral Surgery Followed By Low-Dose or Standard-Dose Radiation Therapy With or Without Chemotherapy in Treating Patients With HPV Positive Stage III-IVA Oropharyngeal Cancer
Not Recruiting
More
This randomized phase II trial studies how well transoral surgery followed by low-dose or
standard-dose radiation therapy works in treating patients with human papilloma virus (HPV)
positive stage III-IVA oropharyngeal cancer. Radiation therapy uses high-energy x-rays to
kill tumor cells. Drugs used in chemotherapy work in different ways to stop the growth of
tumor cells, either by killing the cells or by stopping them from dividing. Giving radiation
therapy with chemotherapy may kill any tumor cells that remain after surgery. It is not yet
known how much extra treatment needs to be given after surgery.
Stanford is currently not accepting patients for this trial.
For more information, please contact Ekaterina Dib, 650-723-0503.
Stanford Investigators
View full details
-
Phase 1 Trial of Hu5F9-G4, a CD47-targeting Antibody
Not Recruiting
More
The purpose of this study is to assess the safety and tolerability of Hu5F9-G4 in
participants with solid tumors.
Stanford is currently not accepting patients for this trial.
For more information, please contact Contact, 650-498-4331.
Stanford Investigators
View full details
-
Phase II Bevacizumab, Gemcitabine and Carboplatin in Newly Diagnosed Non-Small Cell Lung Cancer
Not Recruiting
More
A multi-center study of bevacizumab in combination with gemcitabine and carboplatin as
treatment for newly-diagnosed advanced non-small cell lung cancer (NSCLC).
Stanford is currently not accepting patients for this trial.
For more information, please contact Melanie San Pedro-Salcedo, 6507241388.
Lead Sponsor
Stanford Investigators
View full details
-
Erlotinib With or Without Hydroxychloroquine in Chemo-Naive Advanced NSCLC and (EGFR) Mutations
Not Recruiting
More
The purpose of this research study is to learn if adding hydroxychloroquine (HCQ) to
erlotinib helps treat non-small cell lung cancer (NSCLC). Another goal of this research study
is to learn more about NSCLC and how it may respond to study treatment. Erlotinib (Tarceva)
is a type of drug called a tyrosine kinase inhibitor (TKI). TKIs block a protein called the
epidermal growth factor receptor (EGFR). EGFR may control tumor growth and tumor cell
survival. However, although TKI drugs can work for some lung cancer patients for a period of
time, eventually the tumor finds a way to resist or counteract the TKI treatment and it
begins to grow again. Hydroxychloroquine (HCQ) is a drug approved by the FDA for treating
malaria, rheumatoid arthritis, and several other diseases. Laboratory research suggests that
when HCQ is given with a TKI, it may help delay or prevent TKI resistance from developing.
Stanford is currently not accepting patients for this trial.
For more information, please contact Zeina Babetty, 6507232983.
Stanford Investigators
View full details
-
Phase 2 Etirinotecan Pegol in Refractory Brain Metastases & Advanced Lung Cancer / Metastatic Breast Cancer
Not Recruiting
More
This phase 2 trial evaluates how well pegylated irinotecan (NKTR-102) works in treating
patients with non-small cell lung cancer (NSCLC), small cell lung cancer (SCLC), or breast
cancer (mBC) that has spread to the brain and does not respond to treatment. Pegylated
irinotecan may stop the growth of tumor cells by blocking some of the enzymes needed for cell
growth.
Stanford is currently not accepting patients for this trial.
For more information, please contact Sophie Bertrand, 650-723-4467.
Stanford Investigators
View full details
-
A Study of Onartuzumab (MetMAb) Versus Placebo in Combination With Paclitaxel Plus Platinum in Patients With Squamous Non-Small Cell Lung Cancer
Not Recruiting
More
This multicenter, randomized, double-blind, placebo-controlled study will evaluate the
efficacy and safety of onartuzumab (MetMAb) in combination with paclitaxel plus platinum in
patients with incurable Stage IIIB or Stage IV squamous non-small cell lung cancer (NSCLC).
Patients will be randomized to receive either onartuzumab (MetMAb) 15 mg/kg iv or placebo on
Day 1 of each 21-day cycle in combination with 4 cycles of paclitaxel 200 mg/m2 iv and
platinum (carboplatin/cisplatin) iv on Day 1 of each 21-day cycle. Patients who have not
progressed after 4 cycles will continue with either onartuzumab (MetMAb) or placebo as
maintenance therapy until disease progression or unacceptable toxicity occurs.
Stanford is currently not accepting patients for this trial.
For more information, please contact Melanie San Pedro-Salcedo, 6507241388.
Stanford Investigators
View full details
-
A Study of Aflibercept Administered in Combination With Pemetrexed and Cisplatin in Participants With Advanced Carcinoma
Not Recruiting
More
The purpose of the study was to determine whether the combination of aflibercept, pemetrexed
and cisplatin is safe and effective in treating non-small cell lung cancer (NSCLC).
Stanford is currently not accepting patients for this trial.
For more information, please contact Melanie San Pedro-Salcedo, 6507241388.
Stanford Investigators
View full details
-
Phase 1 Erlotinib and Dovitinib (TKI258) in Advanced Non-small Cell Lung Cancer (NSCLC)
Not Recruiting
More
This phase I trial studies the side effects and best dose of giving erlotinib and dovitinib
together to treat patients with metastatic non-small cell lung cancer. Erlotinib blocks the
epidermal growth factor receptor (EGFR) and has known activity in non-small cell lung cancer
and dovitinib blocks the fibroblast growth factor receptor (FGFR) and other targets which may
be important to treat lung cancer. The combination of both drugs may work better than either
drug alone, but may also have increased side effects. This trial will look at the side
effects of combining the drugs and look for how effective the combination may be.
Stanford is currently not accepting patients for this trial.
For more information, please contact Lisa Zhou, 6507364112.
Stanford Investigators
View full details
-
An Investigational Drug, PF-02341066 Is Being Studied Versus Standard Of Care In Patients With Advanced Non-Small Cell Lung Cancer With A Specific Gene Profile Involving The Anaplastic Lymphoma Kinase (ALK) Gene
Not Recruiting
More
This is a Phase 3 trial comparing the safety and anti-tumor activity of PF-02341066 versus
pemetrexed or docetaxel in patients with advanced non-small cell lung cancer with specific
gene profile involving the ALK gene after failure of one previous chemotherapy regimen that
included one platinum drug.
Stanford is currently not accepting patients for this trial.
For more information, please contact Melanie San Pedro-Salcedo, 6507241388.
Stanford Investigators
View full details
-
Study of Cabozantinib (XL184) in Adults With Advanced Malignancies
Not Recruiting
More
The purpose of this study is to determine whether or not XL184 demonstrates anti-tumor
activity in selected tumor types under a randomized discontinuation trial (RDT) design.
Subjects who have responded to study drug after 12 weeks of open-label XL184 administration
will continue to take XL184. Subjects who are clearly progressing will discontinue study
treatment and subjects who demonstrate stable disease will be randomized to either XL184 or
placebo. For individual patients, once disease progression is observed, the blind will be
broken and subjects who were randomized to placebo will be offered the option to receive
open-label XL184. Subjects who progressed while taking XL184 will discontinue study
treatment.
Emerging data may support enrollment in an open-label, non-randomized expansion cohort (NRE).
There will be NRE cohorts for prostate and ovarian cancers.
Stanford is currently not accepting patients for this trial.
For more information, please contact Dana Supan, 6507361694.
Stanford Investigators
View full details
-
Erlotinib Plus Tivantinib (ARQ 197) Versus Single Agent Chemotherapy in Locally Advanced or Metastatic Non-Small Cell Lung Cancer
Not Recruiting
More
The purpose of this study is to evaluate progression-free survival among subjects with KRAS
mutation positive Non-Small Cell Lung Cancer (NSCLC) treated with erlotinib plus tivantinib
(ARQ 197) compared to single agent chemotherapy.
Stanford is currently not accepting patients for this trial.
For more information, please contact Lei Shura, 650-723-2312.
Stanford Investigators
View full details
-
Study of XL647 in Subjects With NSCLC Who Have Progressed After Responding to Treatment With Gefitinib or Erlotinib
Not Recruiting
More
The purpose of this study is to determine the best confirmed response rate of daily
administration of the multiple receptor tyrosine kinase (RTK) inhibitor (including EGFR and
VEGFR2) XL647 in subjects with NSCLC who have progressed after responding to treatment with
either erlotinib or gefitinib.
Stanford is currently not accepting patients for this trial.
For more information, please contact Lisa Zhou, 6507364112.
Stanford Investigators
View full details
-
A Study of CDX-1127 (Varlilumab) in Patients With Select Solid Tumor Types or Hematologic Cancers
Not Recruiting
More
This is a study of CDX-1127, a therapy that targets the immune system and may act to promote
anti-cancer effects. The study enrolls patients with hematologic cancers (certain leukemias
and lymphomas), as well as patients with select types of solid tumors.
Stanford is currently not accepting patients for this trial.
For more information, please contact Jennifer Vargas, 650-723-0371.
Stanford Investigators
View full details
-
Clinical Study of BYM338 for the Treatment of Unintentional Weight Loss in Patients With Cancer of the Lung or the Pancreas
Not Recruiting
More
A safety & efficacy clinical study of the investigational medicinal product BYM338 for the
treatment of unintentional weight loss in patients with cancer of the lung or the pancreas
Stanford is currently not accepting patients for this trial.
For more information, please contact Melanie San Pedro-Salcedo, 6507241388.
Stanford Investigators
View full details
-
A Study of Enzastaurin and Erlotinib in Participants With Solid Tumors and Lung Cancer
Not Recruiting
More
Phase I: A study to see what doses of Enzastaurin and Erlotinib are best tolerated by
participants with solid tumor cancer.
Phase II: A study to see how long participants with non-small cell lung cancer (NSCLC)
treated with Enzastaurin and Erlotinib live.
Stanford is currently not accepting patients for this trial.
For more information, please contact Melanie San Pedro-Salcedo, 6507241388.
Stanford Investigators
View full details
-
Talactoferrin in Treating Patients With Relapsed or Refractory Non-Small Cell Lung Cancer or Squamous Cell Head and Neck Cancer
Not Recruiting
More
This phase I trial studies how well talactoferrin works in treating patients with relapsed or
refractory non-small cell lung cancer (NSCLC) or squamous cell head and neck cancer.
Biological therapies, such as talactoferrin, may stimulate the immune system in different
ways and stop tumor cells from growing
Stanford is currently not accepting patients for this trial.
For more information, please contact Melanie San Pedro-Salcedo, 6507241388.
Lead Sponsor
Stanford Investigators
View full details
-
Cisplatin and Etoposide With or Without Veliparib in Treating Patients With Extensive Stage Small Cell Lung Cancer
Not Recruiting
More
This randomized phase I/II trial studies the side effects and best dose of veliparib when
given together with or without cisplatin and etoposide and to see how well they work in
treating patients with extensive stage small cell lung cancer or large cell neuroendocrine
non-small cell lung cancer that has spread to other parts of the body. Drugs used in
chemotherapy, such as cisplatin and etoposide, work in different ways to stop the growth of
tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them
from spreading. Veliparib may stop the growth of tumor cells by blocking some of the enzymes
needed for cell growth. Giving cisplatin and etoposide with or without veliparib may work
better in treating patients with extensive stage small cell lung cancer or metastatic large
cell neuroendocrine non-small cell lung cancer.
Stanford is currently not accepting patients for this trial.
For more information, please contact Maria Pitsiouni, 650-721-6977.
Stanford Investigators
View full details
-
A Study of HGS1036 in Combination With Chemotherapy in Subjects With Advanced Solid Malignancies
Not Recruiting
More
The primary purpose of this study is to determine the maximally tolerated dose (MTD) of
HGS1036 when used in combination with the standard chemotherapeutic regimens paclitaxel plus
carboplatin, cisplatin plus etoposide, or docetaxel.
Stanford is currently not accepting patients for this trial.
For more information, please contact Jennifer Vargas, 650-723-0371 .
Stanford Investigators
View full details
-
A Phase II Study to Evaluate the Efficacy and Safety of Oral Ceritinib in Patients With ALK-positive NSCLC Metastatic to the Brain and/or to Leptomeninges
Not Recruiting
More
This was a phase II, multi-center, open-label, five-arm study in which the efficacy and
safety of oral ceritinib treatment was assessed in patients with NSCLC metastatic to the
brain and/or to leptomeninges harboring a confirmed ALK rearrangement, using the FDA approved
Vysis ALK Break Apart FISH Probe Kit (Abbott Molecular Inc.) test and scoring algorithm
(including positivity criteria). If documentation of ALK rearrangement as described above was
not locally available, a test to confirm ALK rearrangement was performed by a Novartis
designated central laboratory. Patients waited for the central laboratory result of the ALK
rearrangement status before initiating treatment with ceritinib.
Stanford is currently not accepting patients for this trial.
For more information, please contact Richard A Quick, 650-724-1388.
Stanford Investigators
View full details
-
Safety and Efficacy Clinical Study of SNS-595 in Patients With Advanced Small Cell Lung Cancer
Not Recruiting
More
The purpose of this study is to evaluate the objective tumor response rate to SNS-595 in
patients with small cell lung cancer (SCLC).
Stanford is currently not accepting patients for this trial.
For more information, please contact Lisa Zhou, 6507364112.
Stanford Investigators
View full details
-
Chemotherapy With or Without Bevacizumab in Treating Patients With Stage IB, Stage II, or Stage IIIA Non-small Cell Lung Cancer That Was Removed By Surgery
Not Recruiting
More
This randomized phase III trial studies chemotherapy and bevacizumab to see how well they
work compared to chemotherapy alone in treating patients with stage IB, stage II, or stage
IIIA non-small cell lung cancer that was removed by surgery. Drugs used in chemotherapy work
in different ways to stop the growth of tumor cells, either by killing the cells, by stopping
them from dividing, or by stopping them from spreading. Giving more than one drug
(combination chemotherapy) may kill more tumor cells. Monoclonal antibodies, such as
bevacizumab, may interfere with the ability of tumor cells to grow and spread. Bevacizumab
also may stop the growth of non-small cell lung cancer by blocking the growth of new blood
vessels necessary for tumor growth. It is not yet known whether chemotherapy is more
effective with or without bevacizumab in treating non-small cell lung cancer.
Stanford is currently not accepting patients for this trial.
For more information, please contact Maria Pitsiouni, 650-721-6977.
Stanford Investigators
View full details
-
Trial of Nivolumab vs Therapy of Investigator's Choice in Recurrent or Metastatic Head and Neck Carcinoma (CheckMate 141)
Not Recruiting
More
The purpose of this study is to find out whether Nivolumab will significantly improve overall
survival as compared to therapy of investigator's choice in patients with recurrent or
metastatic head and neck carcinoma.
Stanford is currently not accepting patients for this trial.
For more information, please contact Risa Jiron, 650-736-1598.
Stanford Investigators
View full details
-
Tivantinib With or Without Erlotinib Hydrochloride in Treating Patients With Metastatic or Locally Advanced Kidney Cancer That Cannot Be Removed by Surgery
Not Recruiting
More
This randomized phase II trial studies how well tivantinib with or without erlotinib
hydrochloride works in treating patients with metastatic or locally advanced kidney cancer
that cannot be removed by surgery. Tivantinib and erlotinib hydrochloride may stop the growth
of tumor cells by blocking some of the enzymes needed for cell growth.
Stanford is currently not accepting patients for this trial.
For more information, please contact Preeti Chavan, 650-725-0426.
Stanford Investigators
View full details
-
Microarray Analysis of Gene Expression and Identification of Progenitor Cells in Lung Carcinoma
Not Recruiting
More
This study will help us understand the gene expression profiles of lung cancer. We will
identify genes related to lung cancer development, their growth and metastasis to the lung.
In addition, we will examine the role nicotine in the development and progression of lung
tumors of smokers, ex-smokers, non-smokers on supplemental nicotine and non smokers with no
exposure to nicotine.
Stanford is currently not accepting patients for this trial.
For more information, please contact Susan Jacobs, RN, 650-725-8082.
Lead Sponsor
Stanford Investigators
View full details
-
An Observational Study of the Ethnic Impact of Patients Undergoing Second (2nd) Line Treatment for Non-Small Cell Lung Cancer Using Pemetrexed
Not Recruiting
More
This large, non-randomized observational study is being conducted to provide data about the
impact of ethnic origin on outcomes and resource utilization during the 2nd line treatment of
non-small cell lung cancer (NSCLC) in a routine medical care setting.
Stanford is currently not accepting patients for this trial.
For more information, please contact Lisa Zhou, 6507364112.
Stanford Investigators
View full details
-
Chemotherapy and Radiation Therapy With or Without Panitumumab in Treating Patients With Stage IIIA Non-Small Cell Lung Cancer
Not Recruiting
More
RATIONALE: Drugs used in chemotherapy (CT), such as paclitaxel and carboplatin, work in
different ways to stop the growth of tumor cells, either by killing the cells or by stopping
them from dividing. Radiation therapy (RT) uses high-energy x-rays to kill tumor cells.
Monoclonal antibodies, such as panitumumab, can block tumor growth in different ways. Some
block the ability of tumor cells to grow and spread. Others find tumor cells and help kill
them or carry tumor-killing substances to them. Giving these treatments before surgery may
make the tumor smaller and reduce the amount of normal tissue that needs to be removed. It is
not yet known whether chemotherapy and radiation therapy are more effective when given with
or without panitumumab in treating patients with non-small cell lung cancer.
PURPOSE: This randomized phase II trial is studying chemotherapy and radiation therapy to see
how well they work when given with or without panitumumab in treating patients with stage
IIIA non-small cell lung cancer.
Stanford is currently not accepting patients for this trial.
For more information, please contact Laura Gable, 6507360798.
Stanford Investigators
View full details
-
Phase 2 Trial of Bevacizumab in Combination With Pemetrexed
Not Recruiting
More
This trial evaluated the safety of combining bevacizumab and pemetrexed in non-small cell
lung cancer (NSCLC) patients with stable brain metastases as second-line chemotherapy, while
evaluating progression-free survival (PFS) and overall survival (OS).
Stanford is currently not accepting patients for this trial.
For more information, please contact Melanie San Pedro-Salcedo, 6507241388.
Stanford Investigators
View full details
-
LDK378 in Adult Patients With ALK-activated NSCLC Previously Treated With Chemotherapy and Crizotinib
Not Recruiting
More
A single-arm, open-label, multicenter, phase II study. Treatment with LDK378 750 mg qd
continued until the patient experienced unacceptable toxicity that precluded further
treatment, discontinued treatment at the discretion of the investigator or patient, started a
new anti-cancer therapy and/or died. LDK378 could be continued beyond RECIST-defined
progressive disease (PD) as assessed by the investigator if, in the judgment of the
investigator, there was evidence of clinical benefit. In these patients tumor assessment
would continue as per the schedule of assessments until treatment with LDK378 was permanently
discontinued. Patients who discontinued the study medication in the absence of progression
continued to be followed for tumor assessment until the time of PD as assessed by the
investigator
Stanford is currently not accepting patients for this trial.
For more information, please contact Melanie San Pedro-Salcedo , 650-724-1388.
Stanford Investigators
View full details
-
CT-2103/Carboplatin vs Paclitaxel/Carboplatin for NSCLC in Women With Estradiol > 25 pg/mL
Not Recruiting
More
This study is designed to test whether CT-2103/carboplatin provides improved overall survival
compared to paclitaxel/carboplatin in women with NSCLC who have estradiol levels >30 pg/ml.
Stanford is currently not accepting patients for this trial.
For more information, please contact Melanie San Pedro-Salcedo, 6507241388.
Stanford Investigators
View full details
-
Study to Evaluate Safety, Pharmacokinetics, and Efficacy of Rociletinib (CO-1686) in Previously Treated Mutant Epidermal Growth Factor Receptor (EGFR) in Non-Small Cell Lung Cancer (NSCLC) Patients
Not Recruiting
More
Rociletinib is a novel, potent, small molecule irreversible tyrosine kinase inhibitor (TKI)
that selectively targets mutant forms of the epidermal growth factor receptor (EGFR) while
sparing wild-type (WT) EGFR. The purpose of the study is to evaluate the pharmacokinetic (PK)
and safety profile of oral rociletinib; to determine the maximum tolerated dose (MTD) and/or
recommended Phase 2 dose (RP2D) of oral rociletinib; to assess the safety and efficacy of
rociletinib in previously treated NSCLC patients known to have the T790M EGFR mutation.
Stanford is currently not accepting patients for this trial.
For more information, please contact Melanie San Pedro Salcedo, 650-724-1388.
Stanford Investigators
View full details
-
A Phase I/II Study of Bexarotene in Combination With ZD1839 (IRESSA®) in the Treatment of Non-Small Cell Lung Cancer
Not Recruiting
More
The purpose of Phase 1 of this study is to evaluate the safety of the combination regimen,
bexarotene and ZD1839. Phase II will evaluate the median survival, time to disease
progression, and toxicity.
Stanford is currently not accepting patients for this trial.
For more information, please contact Lisa Zhou, 6507364112.
Lead Sponsor
Stanford Investigators
View full details
-
Immunobiology of Cancer
Not Recruiting
More
To learn whether or not an Interferon defect in cell signaling, recently discovered in immune
cells from melanoma patients as well as breast cancer patients, is common to all cancers.
Stanford is currently not accepting patients for this trial.
For more information, please contact Diana Simons, 6504987943.
Lead Sponsor
Stanford Investigators
View full details
